NCT05453279View on ClinicalTrials.gov

A Dose Escalation Phase 1 Study Evaluating the Safety and Pharmacokinetics of an Inhaled COVID-19 Inhibitor Delcetravir in Healthy Subjects

PHASE1UnknownINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

November 1, 2022

Study Completion Date

January 1, 2023

Conditions
COVID-19
Interventions
COMBINATION_PRODUCT

Delcetravir dry powder inhaler

Placebo dry powder inhaler

Sponsors
All Listed Sponsors
lead

Esfam Biotech Pty Ltd

INDUSTRY